2024-01-02 08:24:37 ET
DENVER, Colo., Jan. 2, 2024 ( www.247marketnews.com )- Voyager Therapeutics, Inc. (NASDAQ: VYGR) reported, this morning, that it formed a strategic collaboration and capsid license agreement with a Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Voyager is slated to receive up-front consideration of $100 million and is eligible to receive milestone payments and tiered royalties for providing Novartis a target-exclusive license to access Voyager’s TRACER capsids and other intellectual property for the respective diseases, and Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for HD.
Voyager Therapeutics is trading at $10.36, up $1.92 (+22.75%), on 1.27M shares traded.
Its 52-week range is $5.87 to $14.3398. …
The post Trading Volume Alert on License Agreement and Strategic Collaboration to Advance Novel Gene Therapies appeared first on 24/7 Market News .
For further details see:
Trading Volume Alert on License Agreement and Strategic Collaboration to Advance Novel Gene Therapies